Introduction of Wuhan Renfu Pharmaceutical Co., Ltd.

Wuhan Renfu Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Wuhan Renfu Pharmaceutical Group Co., Ltd. (listed on the Shanghai Stock Exchange, referred to as "Renfu Medicine", code 600079), one of the top 100 pharmaceutical enterprises in China. The company has a sales team of nearly 200 people. The company is located in Wuhan National Bio-industrial Park, covering an area of 52,000 square meters. According to the international cGMP and the new GMP standard, the workshop of oral preparation, injection and biochemical extraction has been established, with the production capacity of 7 dosage forms. The company has 62 products, mainly used in the central nervous system, and also used in children's fever reduction and gynecology. The main products are: oxcarbazepine tablets, deproteinized calf blood extract injection, ibuprofen suspension, three-dimensional nystatin suppository, acetylkitasamycin capsules, omeprazole sodium for injection and Yanhuning for injection.